XML 40 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENT AND GEOGRAPHIC AREA INFORMATION
12 Months Ended
Sep. 30, 2022
SEGMENT AND GEOGRAPHIC AREA INFORMATION  
SEGMENT AND GEOGRAPHIC AREA INFORMATION

NOTE L – SEGMENT AND GEOGRAPHIC AREA INFORMATION

As detailed in Note C above, the Company has three reportable segments. (1) Therapeutic DNA Production Services (2) MDx Testing Services, and (3)DNA Tagging and Security Products and Services. Resources are allocated by our CEO, COO, CFO and CLO whom, collectively the Company has determined to be our Chief Operating Decision Maker (CODM).

Information regarding operations by segment for the twelve- month period ended September 30, 2022 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

Production

    

Services 

    

Security Products

    

Consolidated

Revenues:

 

  

 

  

 

  

 

  

Product revenues

$

$

628,286

$

1,254,518

$

1,882,804

Service revenues

 

439,355

 

 

319,783

 

759,138

Clinical laboratory service revenues

 

 

15,979,631

 

 

15,979,631

Less intersegment revenues

 

 

(452,896)

 

 

(452,896)

Total revenues

 

439,355

16,155,021

 

1,574,301

 

18,168,677

Gross profit

 

439,355

 

4,827,672

 

(213,387)

 

5,053,640

Loss from segment operations (a)

 

(4,497,699)

 

(464,894)

 

(4,652,786)

 

(9,615,379)

Information regarding operations by segment for the twelve- month period ended September 30, 2021 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

Production

    

Services 

    

Security Products

    

Consolidated

Revenues:

Product revenues

$

$

1,943,697

$

1,352,152

$

3,295,849

Service revenues

 

559,319

 

 

378,416

 

937,735

Clinical laboratory service revenues

 

 

5,090,794

 

 

5,090,794

Less intersegment revenues

 

 

(296,640)

 

 

(296,640)

Total revenues

 

559,319

 

6,737,851

 

1,730,568

 

9,027,738

Gross profit

 

559,318

 

3,327,080

 

596,508

 

4,482,906

Loss from segment operations (a)

 

(5,214,221)

 

(274,250)

 

(4,823,348)

 

(10,311,819)

Reconciliation of segment loss from operations to corporate loss:

    

2022

2021

Loss from operations of reportable segments

    

$

(9,615,379)

    

$

(10,311,819)

General corporate expenses (b)

 

(4,354,384)

 

(3,036,822)

Interest income (expense), net

 

7,200

 

13,675

Unrealized gain on change in fair value of warrants

17,999,521

Transaction costs related to warrant liabilities

(1,668,112)

Loss on issuance of warrants

(10,591,600)

Loss on extinguishment of convertible notes payable

 

 

(1,774,662)

Gain on extinguishment of notes payable

 

 

839,945

Other expense, net

 

(47,305)

 

(8,756)

Consolidated loss before provision for income taxes

$

(8,270,059)

$

(14,278,439)

(a)

Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)

General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.

NOTE L – SEGMENT AND GEOGRAPHIC AREA INFORMATION, continued

The Company attributes net revenues from external customers according to the geographic location of the customer. Net revenues by geographic location of customers are as follows:

Year Ended September 30, 

    

2022

    

2021

Americas

$

17,544,444

$

8,520,336

Europe

 

448,847

 

359,509

Asia and other

 

175,386

 

147,893

Total

$

18,168,677

$

9,027,738